Building Upon Discovery
Our Focus
E3 Therapeutics Inc. is a biotech company focusing on the selective and efficient ubiquitination of proteins that play a role in the development and proliferation of diseases. E3 utilizes a proprietary amalgam of next-gen technologies—including artificial intelligence, computational chemistry, and medicinal and synthetic chemistry that facilitate the drug discovery and development process. E3 is focused on applying their novel technology/platform to therapeutic programs ranging from oncology, inflammatory and cardiovascular and central nervous system diseases.
Our Mission
To build innovative discovery & development platforms for the creation of new drug candidates.
The Founders
Dr. Fahlman is a professor in the Department of Biochemistry and Oncology at the University of Alberta, and the director of the Alberta Proteomics and Mass Spectrometry core facility at the University of Alberta. He is a current grant panel member for the Cancer Biology and Therapeutics panel for the Canadian Institutes for Health Research (CIHR) and the Canadian Cancer Society. He serves as a scientific advisor to many technology companies.
Dr. Fahlman is an expert in the field of applied and analytical biochemistry. His current research expertise is on auto-immunity and oncology with specific molecular focus on proteostasis mechanism in these diseases. Professor Fahlman is also an expert and pioneer in the field of protein degradation targeted chimeras. Dr. Fahlman has 25 years of research experience and is an inventor of two patents and an author of 61 publications.
Dr. Tuszynski is a Fellow of the National Institute for Nanotechnology of Canada. He is an Allard Chair and Professor in Experimental Oncology in the Department of Oncology at the University of Alberta’s Cross Cancer Institute and a Professor in the Department of Physics. Dr. Tuszynski has published nearly 400 peer-reviewed papers, 10 book chapters and 10 books; delivered over 400 scientific talks (including 150+ invited talks) on five continents.
Dr. Tuszynski heads a multi-disciplinary team creating “designer drugs” for cancer chemotherapy using computational biophysics methods. To make advances in this new promising field of biophysical modeling, he drew on his physics background to create computer software programs that screen proteins against chemical compounds to find the perfect match based on the lock and key principle. The goal of Tuszynski’s computational biophysics work is to create optimized drugs that would target cancerous cells with minimal side-effects to the healthy cells.
Dr. Holsworth is a drug discovery expert, medicinal chemist and entrepreneur with 30 years of research experience. He has held senior positions in multiple pharmaceutical companies, including as a Research Fellow at Pfizer. His research focuses on inflammation, oncology, cardiovascular and dermatology therapeutic areas and has developed seven clinical drug candidates. Dr. Holsworth holds 29 patents, and has published 42 papers and 4 monographs.
Dr. Holsworth is an editorial board member of the Open Access Journal of Medicinal Chemistry, the International Journal of Organic and Medicinal Chemistry, and the Journal of Life Sciences.
Dr. Yao is an experienced medicinal chemist, synthetic chemist, and an entrepreneur with more than 10 years of management experience in biotech and pharmaceutical companies. Since 2009, Dr. Yao has founded or co-founded chemical research organizations and biotech companies. As a trained scientist, Dr. Yao has had the joy and challenge of growing businesses from scratch and learning how to marry his scientific expertise with the business world.